This episode reviews the 2025 ACE consensus framework for individualized obesity pharmacotherapy, moving beyond standardized algorithms toward condition based medication selection. Emphasis is placed on comorbidities, organ specific risk stratification, safety monitoring, and long term therapeutic benefit to support precision management of adiposity based chronic disease.